OverviewSuggest Edit

Invitae is a company engaged in medical genetic testing. It specializes in genetic diagnostics for hereditary disorders. The company offers genetic tests in various clinical areas including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases, as well as prenatal and perinatal genetic tests.

TypePublic
Founded2010
HQSan Francisco, CA, US
Websiteinvitae.com
Employee Ratings4
Overall CultureA-

Latest Updates

Employees (est.) (Dec 2019)1,300(+65%)
Job Openings354
Revenue (FY, 2020)$279.6 M(+29%)
Share Price (Sept 2021)$31.7(+2%)
Cybersecurity ratingBMore

Key People/Management at Invitae

Sean George

Sean George

Chief Executive Officer and Co-Founder
Michele Cargill

Michele Cargill

Co-Founder, Key Projects and Advisor to the CEO
Lee Bendekgey

Lee Bendekgey

Chief Policy Officer
Robbie Evans

Robbie Evans

Chief Strategy Officer
Tom Brida

Tom Brida

General Counsel, Chief Compliance Officer and Secretary
Alex Furman

Alex Furman

Co-Founder, Head of Organizational Development
Show more

Invitae Office Locations

Invitae has an office in San Francisco
San Francisco, CA, US (HQ)
1400 16th St, San Francisco
Show all (1)

Invitae Financials and Metrics

Invitae Revenue

Embed Graph
View revenue for all periods
Invitae's revenue was reported to be $279.6 m in FY, 2020
USD

Revenue (Q1, 2021)

103.6m

Gross profit (Q1, 2021)

28.1m

Gross profit margin (Q1, 2021), %

27.1%

Net income (Q1, 2021)

(109.5m)

EBIT (Q1, 2021)

(112.4m)

Market capitalization (9-Sept-2021)

6.3b

Closing stock price (9-Sept-2021)

31.7

Cash (31-Mar-2021)

194.2m

EV

6.7b
Invitae's current market capitalization is $6.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

68.2m147.7m216.8m279.6m

Revenue growth, %

117%47%

Cost of goods sold

50.1m80.1m118.1m198.3m

Gross profit

18.1m67.6m98.7m81.3m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

27.7m37.3m37.4m40.6m53.5m56.5m64.2m46.2m68.7m103.6m

Cost of goods sold

18.1m20.4m20.4m21.3m28.0m32.1m40.4m43.0m46.6m75.5m

Gross profit

9.6m16.9m16.9m19.3m25.5m24.4m23.8m3.2m22.1m28.1m

Gross profit Margin, %

35%45%45%48%48%43%37%7%32%27%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

12.1m112.2m151.4m124.8m

Accounts Receivable

10.4m26.3m32.5m47.7m

Prepaid Expenses

11.6m13.3m18.0m20.2m

Inventories

32.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

18.4m48.6m101.4m252.5m247.0m467.0m90.2m168.2m106.4m194.2m

Accounts Receivable

21.5m25.1m25.5m23.7m23.1m26.7m37.7m27.9m27.3m45.6m

Prepaid Expenses

12.8m12.3m12.7m16.6m17.0m14.5m25.1m21.1m26.5m31.9m

Inventories

30.7m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(123.4m)(129.4m)(242.0m)(602.2m)

Depreciation and Amortization

9.2m13.5m16.2m39.1m

Inventories

(7.8m)

Accounts Payable

(535.0k)(417.0k)1.6m10.2m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(36.1m)(67.8m)(99.5m)(37.7m)(86.4m)(165.1m)(98.5m)(264.9m)(367.8m)(109.5m)

Depreciation and Amortization

3.4m6.9m10.3m3.3m6.7m11.1m6.1m14.5m23.0m16.6m

Inventories

1.4m

Accounts Payable

(1.6m)(3.1m)(1.2m)(307.0k)(4.0m)87.0k13.1m9.2m3.1m10.2m
USDFY, 2017

Revenue/Employee

114.9k

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

1.7 x
Show all financial metrics

Invitae Operating Metrics

FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020

Billable Tests Generated

145 k59 k73 k75 k292 k87 k111 k124 k469 k151 k113 k

Average Revenue per Test

$449$459$500$490$495$455$471$448$453$418$399

Samples Accessioned

150 k64 k73 k78 k303 k94 k111 k129 k482 k154 k120 k

Cost per Sample Accessioned

$335$279$279$262$264$226$252$249$245$262$358
Show all operating metrics

Invitae Acquisitions / Subsidiaries

Company NameDateDeal Size
DiploidMarch 10, 2020$95 m
GenelexMarch 10, 2020$20.7 m
YouScriptMarch 10, 2020$79.3 m
Clear GeneticsNovember 11, 2019
JunglaJuly 11, 2019$50 m
Singular BioJune 20, 2019$55 m
CombiMatrixNovember 15, 2017$33 m
Good Start GeneticsJuly 31, 2017$24.3 m
CancerGene ConnectJune 12, 2017
Clear Genetics, Inc.
Show more

Invitae Revenue Breakdown

Embed Graph

Invitae revenue breakdown by business segment: 98.0% from Test Revenue and 2.0% from Other

Invitae revenue breakdown by geographic segment: 93.4% from United States and 6.6% from Other

Invitae Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Invitae Online and Social Media Presence

Embed Graph

Invitae Company Culture

  • Overall Culture

    A-

    76/100

  • CEO Rating

    A+

    87/100

  • Compensation

    C+

    70/100

Learn more on Comparably

Invitae News and Updates

Invitae to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday,...

Exact Sciences Said to Approach Invitae About Merger

Exact Sciences Said to Approach Invitae About Merger

Thinking about buying stock in Global Blood Therapeutics, Cerus Corp, Coursera, Agrify Corp, or Invitae Corp?

NEW YORK, Aug. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GBT, CERS, COUR, AGFY, and NVTA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Invitae to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

SAN FRANCISCO, July 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021 and will host a conference call and webcast that day at 4:30 p.m....

Pacific Biosciences and Invitae Announce Intent to Expand Collaboration

Collaboration to develop production-scale HiFi Sequencing platformexpected to Include technology from Omniome, Inc.

Invitae appoints technology and medtech veteran Roxi Wen as chief financial officer

SAN FRANCISCO, June 11, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief financial officer, effective June 21, 2021. Wen brings decades of success as a senior financial executive where she scaled global...
Show more

Invitae Blogs

From disempowerment to empowerment

How Telesa broke free from generational cancerPatricia with her daughter TelesaTelesa understands loss due to cancer. She lost her grandfather Levi to lung cancer. Her grandmother Myrtle to breast cancer. Her grandfather Ernest to kidney cancer. Her aunt Darlene to ovarian cancer.Some cancers can ru…

How genetic testing informed this patient’s treatment decisions — for the better.

How genetic testing informed this patient’s treatment decisions — for the better.One simple genetic test provided critical information that changed Sarah’s course of treatment and prevention.Sarah with her family.Shortly after she turned 40, Sarah’s Ob/Gyn scheduled her for her first mammogram, a ro…

Alexis thought her dancing days were over, but a genetic test helped her stay on the stage.

No more worries: How genetic testing helped Alexis dance again after being diagnosed with Long QT syndrome.Alexis is a dancer. From hip-hop to contemporary, dance is where she’s most in her element.Alexis in her element.Alexis’s mother, Meredith, is an Ob-Gyn and, from her medical training, knew som…

Pregnant? What you need to know about genetic testing.

Pregnancy is an exciting time — and also one filled with a lot of questions. While genetic testing can’t tell you everything, it can help answer important questions about your baby’s health so you’re as prepared as possible for their arrival.What information can genetic tests provide during pregnanc…

Invitae’s new functional modeling platform reduces uncertainty in genetic testing

Originally published on Invitae.com on April 15, 2020Genetic testing through DNA sequencing can detect millions of places where one person’s genome differs from another’s. Most of the time, these differences are harmless and deemed benign. Occasionally, they are the cause of disease or a marker of i…

The art (and science) of variant interpretation

The art (and science) of variant interpretation: Invitae’s innovative approachOriginally published on Invitae.com on October 8, 2020 by Jill Polk, Clinical Science Liaison, InvitaeWhen it comes to genetic testing in healthcare, it’s important that a laboratory excels not only at identifying genetic …
Show more

Invitae Frequently Asked Questions

  • When was Invitae founded?

    Invitae was founded in 2010.

  • Who are Invitae key executives?

    Invitae's key executives are Sean George, Michele Cargill and Lee Bendekgey.

  • How many employees does Invitae have?

    Invitae has 1,300 employees.

  • What is Invitae revenue?

    Latest Invitae annual revenue is $279.6 m.

  • What is Invitae revenue per employee?

    Latest Invitae revenue per employee is $215.1 k.

  • Who are Invitae competitors?

    Competitors of Invitae include Natera, Quest Diagnostics and Bio-Reference Laboratories.

  • Where is Invitae headquarters?

    Invitae headquarters is located at 1400 16th St, San Francisco, San Francisco.

  • Where are Invitae offices?

    Invitae has an office in San Francisco.

  • How many offices does Invitae have?

    Invitae has 1 office.